Drug Discovery Stories
portes grátis
Drug Discovery Stories
From Bench to Bedside
Yu, Bin; Zhan, Peng
Elsevier - Health Sciences Division
10/2024
692
Mole
9780443239328
Pré-lançamento - envio 15 a 20 dias após a sua edição
Descrição não disponível.
Section 1: Drug discovery techniques and Strategies 1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery 2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application 3. Hit Discovery from DNA-Encoded Chemical Libraries 4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy 5. Macrocyclization strategy in kinase drug discovery 6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules 7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments 8. A future battle, small molecule drugs for cancer stem cell targeted therapy 9. Stem cell therapies for combating emerging and re-emerging viral infections 10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases 11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role? 12. Selenium and small molecules: a symbiotic partnership 13. Novel Combinations of CD33-Targeted Immunotherapies 14. Novel payloads of antibody-drug conjugates 15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines 16. mRNA Vaccines: The Next Frontier in Disease Prevention 17. Unravelling the drying techniques of protein biopharmaceuticals Section 2: Drug discovery case studies 18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections 19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19 20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer 21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer 22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer 23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community 24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia 25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia 26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor 27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy 28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure 29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis 30. Oliceridine (TRV-130): A Biased Agonist of the ? Opioid Receptor as a Novel Analgesic 31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis 32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin 33. Antidiabetic Drugs Targeted PPAR?: From Full Agonists to Selective Modulators 34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis 35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
<p>New drug discovery; Medicinal chemistry strategy; Privileged scaffolds; Natural products; Peptide-based drugs; Protein degradation</p>
Section 1: Drug discovery techniques and Strategies 1. Artificial Intelligence in Early Stages of Structure-Based Drug Discovery 2. Target-based vs Phenotypic drug discovery: Opportunities and challenges with evidence-based application 3. Hit Discovery from DNA-Encoded Chemical Libraries 4. Discovery of Lead Compounds from Pseudo-Natural Macrocycles Enabled by Modular Biomimetic Strategy 5. Macrocyclization strategy in kinase drug discovery 6. Cobalt catalyzed C-H functionalization for the synthesis of chiral heterocyclic molecules 7. Advancing Proteolysis Targeting Chimeras towards Clinical Drug Developments 8. A future battle, small molecule drugs for cancer stem cell targeted therapy 9. Stem cell therapies for combating emerging and re-emerging viral infections 10. Targeting Autophagy with Pharmacological Small-Molecules to Treat Human Diseases 11. Interferons in human papillomavirus infection: antiviral effectors or immunopathogenic role? 12. Selenium and small molecules: a symbiotic partnership 13. Novel Combinations of CD33-Targeted Immunotherapies 14. Novel payloads of antibody-drug conjugates 15. Antibody-Drug Conjugates (ADCs): A New Generation of Cancer Vaccines 16. mRNA Vaccines: The Next Frontier in Disease Prevention 17. Unravelling the drying techniques of protein biopharmaceuticals Section 2: Drug discovery case studies 18. Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatmet of multidrig-resistant HIV infections 19. Nirmatrelvir, SIM0417, and RAY1216: Potent and Selective SARS-CoV-2 Main Protease Inhibitors for the Potential Treatment of COVID-19 20. ARV-110: An Androgen Receptor Degrader in the Treatment of Metastatic Castration-Resistant Prostate Cancer 21. Darolutamide: An Androgen Receptor Antagonist for the Treatment of Prostate Cancer 22. Palbociclib, Ribociclib, and Abemaciclib: Potent and Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer 23. Zanubrutinib: A breakthrough in cancer therapy targeting BTK, originating from China and benefiting the global community 24. Discovery of FT-2102 (olutasidenib), an inhibitor of mutant isocitrate dehydrogenase 1, for treatment of relapsed or refractory acute myeloid leukemia 25. Ziftomenib (KO-539): A Potent and Selective Menin Inhibitor for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia 26. Pulrodemstat (CC-90011): A Potent, Selective, and Reversible LSD1 Inhibitor 27. Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy 28. Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure 29. Tafamidis: a Transthyretin Stabilizer for Rare Cardiac Amyloidosis 30. Oliceridine (TRV-130): A Biased Agonist of the ? Opioid Receptor as a Novel Analgesic 31. Sotyktu (Deucravacitinib): The First TYK2 Inhibitor Approved for the Treatment of Psoriasis 32. Bexagliflozin: A SGLT-2 Inhibitor as Antidiabetic Drug Derived From Phlorizin 33. Antidiabetic Drugs Targeted PPAR?: From Full Agonists to Selective Modulators 34. Pretomanid: an antibiotic used for the treatment of multidrug-resistant tuberculosis 35. Lecanemab (Leqembi): An Amyloid Beta Monoclonal Antibody Approved for the Treatment of Alzheimer's Disease
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
